查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1613135

先天性腎上腺增生症治療的全球市場（按類型、治療方法和最終用戶）：未來預測（2025-2030）

Congenital Adrenal Hyperplasia Treatment Market by Type (Classic, Non-Classic), Treatments (Corticosteroid, Glucocorticoids, Hormone Replacement Therapy), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

先天性腎上腺增生症治療市場2023年估值為3.8498億美元，預計2024年將達到4.0557億美元，複合年成長率為5.47%，到2030年將達55億美元，預計將達到5896兆美元。

先天性腎上腺增生症(CAH) 治療涉及旨在管理一組影響腎上腺類固醇激素生物合成的遺傳性疾病的醫療通訊協定。這些治療的需求源於控制異常荷爾蒙產生、緩解雙性戀等症狀以及管理潛在的健康併發症（如嚴重脫水、鹽流失和壓力反應受損）的需要。糖皮質激素和鹽皮質激素治療是基石，輔以新興的基因療法和新穎的藥物干預措施。最終用戶範圍從醫院和專科診所到專門從事內分泌學和遺傳學的研究機構。 CAH治療市場的主要成長要素包括對遺傳疾病認知的提高、產前診斷的進步以及對罕見疾病的研發投入的增加。此外，CAH 盛行率的增加和新興國家醫療基礎設施的擴張正在推動市場需求。分析潛在商機，鼓勵企業投資基因編輯技術和精準醫療方法，以提供個人化醫療。與研究機構合作進行臨床試驗可以促進創新治療方法的推出。然而，他們面臨著治療費用上漲、低收入地區獲得先進治療的機會有限以及專業醫護人員短缺等挑戰。此外，克服監管障礙可能會阻礙治療方法的核准速度。有前景的技術創新領域包括 CRISPR 和外顯子跳躍療法，它們具有潛在的療效。該市場的特點是高度專業化和競爭格局，主要企業專注於策略聯盟、併購和收購，以豐富其產品陣容。公司可以透過優先考慮以患者為中心的方法、開發具有成本效益的治療方法以及持續的產品創新來有效滿足未滿足的需求，從而獲得競爭優勢。

主要市場統計
基準年[2023] 38498萬美元
預計年份 [2024] 40557萬美元
預測年份 [2030] 55896萬美元
複合年成長率（%） 5.47%

市場動態：快速發展的先天性腎上腺增生症治療市場的關鍵市場洞察

先天性腎上腺增生症治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 提高對遺傳疾病的認知並改善世界各地的新生兒篩檢計劃
    • 政府對 CAH 治療的優惠政策和報銷政策
  • 市場限制因素
    • 藥品核准的嚴格規定
  • 市場機會
    • CAH 療法的配方和遞送系統的創新
    • 基因編輯和荷爾蒙療法的進展
  • 市場挑戰
    • CAH 治療藥物相關的嚴重副作用

波特五力：開拓先天性腎上腺增生症治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。它為評估公司的競爭力和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解先天性腎上腺增生症治療市場的外在影響

外部宏觀環境因素在塑造先天性腎上腺增生症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解先天性腎上腺增生症治療市場的競爭格局

先天性腎上腺增生症治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：先天性腎上腺增生症治療市場供應商的績效評估

FPNV定位矩陣是評估先天性腎上腺增生症治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製先天性腎上腺增生症治療市場的成功之路

先天性腎上腺增生症治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析最近的產品發布、開拓的地區、關鍵產業進展以及塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1. 目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3. 塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 哪些收益來源和策略機會推動供應商的進入/退出策略？

目錄

第1章簡介

第2章 分析方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人們對遺傳疾病的興趣日益濃厚，國際上在改善新生兒篩檢計畫方面取得了進展
      • 政府對 CAH 治療的優惠政策和報銷政策
    • 抑制因素
      • 藥品核准的嚴格規定
    • 機會
      • CAH 藥物配方和輸送系統的創新
      • 基因編輯和荷爾蒙療法的進展
    • 任務
      • CAH 藥物相關的嚴重副作用
  • 市場區隔分析
    • 類型：首選經典CAH治療，促進新生兒正常生長發育
    • 最終用戶：透過各種醫療保健提供者擴大 CAH 治療的可用性，以解決緊急和全面的情況
  • 波特五力分析
  • PESTEL分析
    • 政治因素
    • 經濟因素
    • 社會因素
    • 技術因素
    • 法律因素
    • 環境因素

第6章先天性腎上腺增生症治療市場：依類型

  • 典型的
  • 非典型的

第7章先天性腎上腺增生症治療市場：依治療方法

  • 皮質類固醇
  • 糖皮質激素
  • 荷爾蒙補充療法
  • 藥物治療
  • 補充鹽分
  • 外科手術

第8章先天性腎上腺增生症治療市場：依最終使用者分類

  • 醫院
  • 藥局
  • 專科診所

第9章 北美和南美先天性腎上腺增生症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區先天性腎上腺增生症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲先天性腎上腺增生症治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭情境分析
    • FDA 加速治療先天性腎上腺增生症口服新藥的核准流程
    • BridgeBio Pharma 與 National Resilience 合作加強基因治療創新
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Adrenas Therapeutics, Inc. by
  • Amgen Inc.
  • BioMarin Pharmaceutical Inc.
  • BridgeBio Pharma
  • EffRx Pharmaceuticals
  • GSK PLC
  • Johnson and Johnson Services, Inc.
  • Merck & Co., Inc.
  • Millendo Therapeutics, Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Spruce Bioscience
  • Thermo Fisher Scientific Inc.
  • Zydus Group
Product Code: MRR-1F14CA1E76C9

The Congenital Adrenal Hyperplasia Treatment Market was valued at USD 384.98 million in 2023, expected to reach USD 405.57 million in 2024, and is projected to grow at a CAGR of 5.47%, to USD 558.96 million by 2030.

Congenital Adrenal Hyperplasia (CAH) treatment encompasses medical protocols aimed at managing a group of inherited disorders affecting adrenal steroid hormone biosynthesis. The necessity for these treatments arises from the need to control abnormal hormone production, reduce symptoms like ambiguous genitalia, and manage potential health complications such as severe dehydration, salt loss, and impaired stress response. Applications span across therapeutic uses in pediatric and adult endocrinology, with glucocorticoid and mineralocorticoid therapies being the cornerstone, complemented by emerging gene therapies and novel pharmacological interventions. End-users range from hospitals and specialty clinics to research institutions focusing on endocrinology and genetics. Key growth influencers in the CAH treatment market include increasing awareness about genetic disorders, advancements in prenatal diagnostics, and rising investments in R&D for rare diseases. Moreover, the growing prevalence of CAH and the expansion of healthcare infrastructure in emerging economies are propelling market demand. Analyzing potential opportunities, companies are encouraged to invest in gene-editing technologies and precision medicine approaches to offer personalized care. Partnerships with research organizations for clinical trials could expedite the introduction of innovative therapies. However, market growth faces challenges such as the high cost of treatment, limited access to advanced therapies in low-income regions, and a scarcity of specialized healthcare professionals. Additionally, navigating regulatory hurdles can impede the pace of therapy approvals. Promising areas of innovation include CRISPR and exon skipping therapies, which offer potential curative benefits. The market is characterized by a high degree of specialization and a competitive landscape with key players focusing on strategic collaborations, mergers, and acquisitions to enhance their product offerings. Firms can gain a competitive advantage by prioritizing patient-centric approaches, developing cost-effective treatments, and engaging in continuous product innovation to address unmet clinical needs effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 384.98 million
Estimated Year [2024] USD 405.57 million
Forecast Year [2030] USD 558.96 million
CAGR (%) 5.47%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Congenital Adrenal Hyperplasia Treatment Market

The Congenital Adrenal Hyperplasia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing awareness related to genetic disorders and improved newborn screening programs globally
    • Favorable government initiatives and reimbursement policies for CAH treatment
  • Market Restraints
    • Strict regulations regarding drug approvals
  • Market Opportunities
    • Innovation in drug formulation and delivery systems for CAH
    • Advancements in gene editing and hormone therapies
  • Market Challenges
    • Significant side effects associated with the CAH drugs

Porter's Five Forces: A Strategic Tool for Navigating the Congenital Adrenal Hyperplasia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Congenital Adrenal Hyperplasia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Congenital Adrenal Hyperplasia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Congenital Adrenal Hyperplasia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Congenital Adrenal Hyperplasia Treatment Market

A detailed market share analysis in the Congenital Adrenal Hyperplasia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Congenital Adrenal Hyperplasia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Congenital Adrenal Hyperplasia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Congenital Adrenal Hyperplasia Treatment Market

A strategic analysis of the Congenital Adrenal Hyperplasia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Congenital Adrenal Hyperplasia Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adrenas Therapeutics, Inc. by, Amgen Inc., BioMarin Pharmaceutical Inc., BridgeBio Pharma, EffRx Pharmaceuticals, GSK PLC, Johnson and Johnson Services, Inc., Merck & Co., Inc., Millendo Therapeutics, Inc., Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., Sanofi SA, Spruce Bioscience, Thermo Fisher Scientific Inc., and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Congenital Adrenal Hyperplasia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Classic and Non-Classic.
  • Based on Treatments, market is studied across Corticosteroid, Glucocorticoids, Hormone Replacement Therapy, Medication, Salt Supplements, and Surgery.
  • Based on End-User, market is studied across Hospitals, Pharmacies, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness related to genetic disorders and improved newborn screening programs globally
      • 5.1.1.2. Favorable government initiatives and reimbursement policies for CAH treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations regarding drug approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovation in drug formulation and delivery systems for CAH
      • 5.1.3.2. Advancements in gene editing and hormone therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Significant side effects associated with the CAH drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Preference for classic CAH treatment due to facilitate normal growth and development in newborns
    • 5.2.2. End-User: Widening availability of CAH treatment thorugh varied healthcare institution to cater urgent and comprehensive conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Congenital Adrenal Hyperplasia Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Classic
  • 6.3. Non-Classic

7. Congenital Adrenal Hyperplasia Treatment Market, by Treatments

  • 7.1. Introduction
  • 7.2. Corticosteroid
  • 7.3. Glucocorticoids
  • 7.4. Hormone Replacement Therapy
  • 7.5. Medication
  • 7.6. Salt Supplements
  • 7.7. Surgery

8. Congenital Adrenal Hyperplasia Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Pharmacies
  • 8.4. Specialty Clinics

9. Americas Congenital Adrenal Hyperplasia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Congenital Adrenal Hyperplasia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Congenital Adrenal Hyperplasia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Accelerates Approval Process for New Oral Drug Treating Congenital Adrenal Hyperplasia
    • 12.3.2. BridgeBio Pharma and National Resilience Forge Partnership to Enhance Gene Therapy Innovations
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adrenas Therapeutics, Inc. by
  • 3. Amgen Inc.
  • 4. BioMarin Pharmaceutical Inc.
  • 5. BridgeBio Pharma
  • 6. EffRx Pharmaceuticals
  • 7. GSK PLC
  • 8. Johnson and Johnson Services, Inc.
  • 9. Merck & Co., Inc.
  • 10. Millendo Therapeutics, Inc.
  • 11. Neurocrine Biosciences, Inc.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sanofi SA
  • 15. Spruce Bioscience
  • 16. Thermo Fisher Scientific Inc.
  • 17. Zydus Group

LIST OF FIGURES

  • FIGURE 1. CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY CLASSIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY NON-CLASSIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY SALT SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. CONGENITAL ADRENAL HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023